FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS
KUALA LUMPUR (Bernama): Solution Group Bhd’s (SGB) wholly-owned subsidiary, Solution Biologics Sdn Bhd (SolBio) has signed a finished product and a bulk product agreement today with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine for use against Covid-19.
In a statement, the group said the finished product agreement allows SolBio to purchase and CanSino to supply the finish product vaccine for emergency use in Malaysia.
Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.
